Posted by Michael Wonder on 13 Apr 2019
Polyphor's antibiotic murepavadin receives US FDA qualified infectious disease product designation in four new indications
12 April 2019 - Polyphor's antibiotic murepavadin receives US FDA qualified infectious disease product designation in four new indications.
Polyphor today announced that the US FDA has designated murepavadin as a qualified infectious disease product in four additional indications; hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infection, bloodstream infection and complicated intra-abdominal infection.
